• 1
    Witkowski JT, Robins RK, Sidwell RW, Simon LN. Design, synthesis, and broad spectrum antiviral activity of 1-β-D-Ribofuranosyl-1,2,4-triazole-3-carboxamide and related nucleosides. J Med Chem 1972; 15:11501154.
  • 2
    Sidwell RW, Huffman JH, Khare GP, Allen LB, Witkowski JT, Robins RK. Broad-spectrum antiviral activity of Virazole: 1-beta-D-ribofuranosyl-1,2,4-triazole-3-carboxamide. Science 1972; 177:705706.
  • 3
    Choo QL, Kuo G, Weiner AJ, Overby LR, Bradley DW, Houghton M. Isolation of a cDNA clone derived from a blood-borne non-A, non-B viral hepatitis genome. Science 1989; 244:359362.
  • 4
    Foster GR. Interferons in host defense. Semin Liver Dis 1997; 17:287295.
  • 5
    Lau JY. Mechanisms of hepatic toxicity. IV. Pathogenetic mechanisms involved in hepatitis C virus-induced liver diseases. Am J Physiol 1998; 275:G1217G1220.
  • 6
    Dusheiko G, Main J, Thomas H, Reichard O, Lee C, Dhillon A, Rassam S, et al. Ribavirin treatment for patients with chronic hepatitis C: results of a placebo-controlled study. J Hepatol 1996; 25:591598.
  • 7
    Bodenheimer HC Jr., Lindsay KL, Davis GL, Lewis JH, Thung SN, Seeff LB. Tolerance and efficacy of oral ribavirin treatment of chronic hepatitis C: a multicenter trial. Hepatology 1997; 26:473477.
  • 8
    Friebe P, Lohmann V, Krieger N, Bartenschlager R. Sequences in the 5' nontranslated region of hepatitis C virus required for RNA replication. J Virol 2001; 75:1204712057.
  • 9
    Kolykhalov AA, Mihalik K, Feinstone SM, Rice CM. Hepatitis C virus-encoded enzymatic activities and conserved RNA elements in the 3' nontranslated region are essential for virus replication in vivo. J Virol 2000; 74:20462051.
  • 10
    Zhong W, Uss AS, Ferrari E, Lau JY, Hong Z. De novo initiation of RNA synthesis by hepatitis C virus nonstructural protein 5B polymerase. J Virol 2000; 74:20172022.
  • 11
    Hong Z, Cameron CE, Walker MP, Castro C, Yao N, Lau JY, Zhong W. A novel mechanism to ensure terminal initiation by hepatitis C virus NS5B polymerase. Virology 2001; 285:611.
  • 12
    Gilles PN, Guerrette DL, Ulevitch RJ, Schreiber RD, Chisari FV. HBsAg retention sensitizes the hepatocyte to injury by physiological concentrations of interferon-gamma. Hepatology 1992; 16:655663.
  • 13
    Mosmann TR, Sad S. The expanding universe of T cell subsets: Th1, Th2 and more. Immunol Today 1996; 17:138146.
  • 14
    Tsai SL, Liaw YF, Chen MH, Huang CY, Kuo GC. Detection of type 2-like T helper cells in hepatitis C virus infection: implications for hepatitis C virus chronicity. Hepatology 1997; 25:449458.
  • 15
    Lechmann M, Woitas RP, Langhans B, Kaiser R, Ihlenfeldt HG, Jung G, Sauerbruch T, et al. Decreased frequency of HCV core-specific peripheral blood mononuclear cells with type 1 cytokine secretion in chronic hepatitis C. J Hepatol 1999; 31:971978.
  • 16
    Reiser M, Marousis CG, Nelson DR, Lauer G, Gonzalez-Peralta RP, Davis GL, Lau JYN. Serum interleukin 4 and interleukin 10 levels in patients with chronic hepatitis C virus infection. J Hepatol 1997; 26:471478.
  • 17
    Cacciarella TV, Martinez OM, Gish RG, Villanueva JC, Krams SM. Immunoregulatory cytokines in chronic hepatitis C virus infection: pre- and post-treatment with interferon alfa. Hepatology 1996; 24:69.
  • 18
    Eckels DD, Tabatabail N, Bian TH, Wang H, Muheisen SS, Rice CM, Yoshizawa K, Gill J. In vitro human Th-cell responses to a recombinant hepatitis C virus antigen: failure in IL-2 production despite proliferation. J Hum Immunol 1999; 60:187199.
  • 19
    Cramp ME, Carucci P, Rossol S, Chokshi S, Maertens G, Williams R, Naomouv NV. Hepatitis C virus (HCV) specific immune responses in anti-HCV positive patients without hepatitis C viraemia. Gut 1999; 44:424429.
  • 20
    Peavy DL, Powers CN, Knight V. Inhibition of plaque-forming cell responses in vivo by ribavirin. J Immunol 1981; 126:861864.
  • 21
    Edell D, Brice E, Hale K, Edell D, Khoshoo V. Reduced long-term respiratory morbidity after treatment of respiratory syncytial virus bronchiolitis with ribavirin in previously healthy infants: a preliminary report. Pediatric Pulmonol 1998; 25:154158.
  • 22
    Tam RC, Pai BP, Bard J, Lim C, Averett DR, Phan UT, Milovanovic T. Ribavirin polarizes human T cell responses towards a type 1 cytokine profile. J Hepatol 1999; 30:376382.
  • 23
    Preston SL, Drusano GL, Glue P, Nash J, Gupta SK, McNamara P. Pharmacokinetics and absolute bioavailability of ribavirin in healthy volunteers as determined by stable-isotope methodology. Antimicrob Agents Chemother 1999; 43:24512456.
  • 24
    Tam RC, Ramasamy K, Bard J, Pai B, Lim C, Averett DR. The ribavirin analog ICN 17261 demonstrates reduced toxicity and antiviral effects with retention of both immunomodulatory activity and reduction of hepatitis-induced serum alanine aminotransferase levels. Antimicrob Agents Chemother 2000; 44:12761283.
  • 25
    Fang SH, Hwang LH, Chen DS, Chiang BL. Ribavirin enhancement of hepatitis C virus core antigen-specific type 1 T helper cell response correlates with the increased IL-12 level. J Hepatol 2000; 33:791798.
  • 26
    Hultgren C, Milich DR, Weiland O, Sällberg M. The antiviral compound ribavirin modulates the T helper Th1/Th2 subset balance in hepatitis B and C virus-specific immune responses. J Gen Virol 1998; 79:23812391.
  • 27
    Ning Q, Brown D, Parodo J, Cattral M, Fung L, Gorczynski R, Cole E, et al. Ribavirin inhibits viral-induced macrophage production of tumor necrosis factor, interleukin-1, procoagulant activity fgl2 prothrombinase and preserves Th1 cytokine production but inhibits Th2 cytokine response. J Immunol 1998; 160:34873493.
  • 28
    He Q, Flaherty J, Cheney CP, Tam RC, Koziel MK. Enhancement of hepatitis C virus-specific type 1 cytokine and T cell proliferative responses by ribavirin and levovirin (ICN17261) in vitro [Abstract]. Hepatology 2000; 32:394A.
  • 29
    Rigopoulou EI, Abbott WGH, Williams R, Lau JYN, Naoumov NV. Direct evidence for the immunomodulatory action of ribavirin on T-cell reactivity to hepatitis C virus (HCV) [Abstract]. Hepatology 2000; 32:374A.
  • 30
    Martin MJ, Navas S, Quiroga JA, Pardo M, Carreno V. Effects of the ribavirin-interferon alpha combination on cultured peripheral blood mononuclear cells from chronic hepatitis C patients. Cytokine 1998; 10:635644.
  • 31
    Rico MA, Quiroga JA, Subira D, Castanon S, Esteban JM, Pardo M, Carreno V. Hepatitis B virus–specific T-cell proliferation and cytokine secretion in chronic hepatitis B e antibody-positive patients treated with ribavirin and interferon alpha. Hepatology 2001; 33:295300.
  • 32
    Cramp ME, Rossol S, Chokshi S, Carucci P, Williams R, Naoumov NV. Hepatitis C virus–specific T-cell reactivity during interferon and ribavirin treatment in chronic hepatitis C. Gastroenterology 2000; 118:346355.
  • 33
    Morishima C, Musey L, Elizaga M, Beyer K, Carithers RL, Gretch DR, McElrath MJ. Improved cell-mediated immune responses to HCV antigens after combination therapy [Abstract]. Hepatology 2000; 32:367A.
  • 34
    Zitron IM, Qu S, Silverman AL, Gordon SC. Peripheral cellular immune responses during Rebetron therapy for chronic HCV infection [Abstract]. Hepatology 2000; 30:374A.
  • 35
    Nelson DR, Marousis CG, Ohno T, Davis GL, Lau JY. Intrahepatic hepatitis C virus-specific cytotoxic T lymphocyte activity and response to interferon alfa therapy in chronic hepatitis C. Hepatology 1998; 28:225230.
  • 36
    Zhang ZX, Milich DR, Peterson DL, Birkett A, Schvarcz R, Weiland O, Sallberg M. Interferon-alpha treatment induces delayed CD4 proliferative responses to the hepatitis C virus nonstructural protein 3 regardless of the outcome of therapy. J Infect Dis 1997; 175:12941301.
  • 37
    Rossi S, Wright TL, Lin CC, Lau JYN, Edalatpour N, Fang JWS. Phase I clinical studies of levovirin—a second generation ribavirin candidate [Abstract]. Hepatology 2001; 34(Part 2):327A.
  • 38
    Willis RC, Carson DA, Seegmiller JE. Adenosine kinase initiates the major route of ribavirin activation in a cultured human cell line. Proc Natl Acad Sci U S A 1978; 75:30423044.
  • 39
    Sintchak MD, Nimmesgern E. The structure of inosine 5'-monophosphate dehydrogenase and the design of novel inhibitors. Immunopharmacology 2000; 47:163184.
  • 40
    Pankiewicz KW, Lesiak-Watanabe K, Watanabe KA, Malinowski K. Novel mycophenolic adenine bis(phosphonate)s as potential immunosuppressants. Curr Med Chem 1999; 6:629634.
  • 41
    Markland W, McQuaid TJ, Jain J, Kwong AD. Broad-spectrum antiviral activity of the IMP dehydrogenase inhibitor VX-497: a comparison with ribavirin and demonstration of antiviral additivity with alpha interferon. Antimicrob Agents Chemother 2000; 44:859866.
  • 42
    Laxton C, Gilbert S, Sully R, Smith K, Thornberry A, Wilkinson T, Bartenschlager R, et al. Characterization of interferon-alfa-2a and pegylated interferon-alfa-2a in combination with ribavirin, mycophenolic acid or VX-497 as inhibitors of HCV replicon replication [Abstract]. 7th International Meeting on Hepatitis and Related Viruses 2000; 338.
  • 43
    Smith RA. Background and mechanisms of action of ribavirin. In: SmithRA, KnightV, SmithJAD, eds. Clinical Applications of Ribavirin. Florida: Academic Press 1984; 118.
  • 44
    Peavy DL, Koff WC, Hyman DS, Knight V. Inhibition of lymphocyte proliferative responses by ribavirin. Infect Immunol 1980; 29:583589.
  • 45
    Wright T, Shiffman ML, Knox S, Ette E, Kauffman RS, Alam J. Dose range-finding study of VX-497, a novel, oral IMPDH inhibitor, in patients with hepatitis C [Abstract]. Hepatology 1999; 30:408A.
  • 46
    Marousis CG, Lau JY. Genetic heterogeneity of hepatitis C virus and its clinical implications. Dig Dis 1997; 15:192206.
  • 47
    Crotty S, Maag D, Arnold JJ, Zhong W, Lau JY, Hong Z, Andino R, Cameron CE. The broad-spectrum antiviral ribonucleoside ribavirin is an RNA virus mutagen. Nat Med 2000; 6:13751379.
  • 48
    Crotty S, Cameron CE, Andino R. RNA virus error catastrophe: direct molecular test by using ribavirin. Proc Natl Acad Sci U S A 2001; 98:68956900.
  • 49
    Lanford RE, Chavez D, Guerra B, Lau JY, Hong Z, Brasky KM, Beames B. Ribavirin induces error prone replication of GBV-B in primary tamarin hepatocytes. J Virol 2001; 75:80748081.
  • 50
    Catlin DH, Smith RA, Samuels AI. 14C-ribavirin distribution and pharmacokinetic studies in rat, baboons, and man. In: SmithRA, KirkpatrickW, eds. Ribavirin: A Broad Spectrum Antiviral Agent. New York: Academic Press, 1980: 8398.